Lisa A. Hayes
Plus aucun poste en cours
Profil
Lisa A.
Hayes worked as Senior Director of Investor Relations at Celgene Corp.
and as Head of Investor Relations & Corporate Communications at ProQR Therapeutics NV and Tmunity Therapeutics, Inc. She also worked as VP of Investor Relations & Corporate Communications at Cyteir Therapeutics, Inc. from 2021 to 2023.
Ms. Hayes holds a graduate degree from New York University, a Master's in Business Administration from St. Joseph's University, and an undergraduate degree from Seton Hall University.
Anciens postes connus de Lisa A. Hayes
| Sociétés | Poste | Fin |
|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Investor Relations Contact | 01/02/2023 |
Tmunity Therapeutics, Inc.
 Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Investor Relations Contact | - |
| PROQR THERAPEUTICS N.V. | Investor Relations Contact | - |
| CELGENE | Public Communications Contact | - |
Formation de Lisa A. Hayes
| St. Joseph's University | Masters Business Admin |
| New York University | Graduate Degree |
| Seton Hall University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PROQR THERAPEUTICS N.V. | Health Technology |
| CYTEIR THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Commercial Services |